Is MITI a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

196 people get MITI articles and Market Currents by email alert.

Get email alerts on MITI »

HEADLINES:

Breaking The Mold Of Oncology Drug Development
Brian Nichols • Tue, Apr 10, 2012 • 7 Comments
Upgrades Lead To Optimism In Cancer Stem Cell Therapy
Brian Nichols • Tue, Mar 13, 2012 • 9 Comments
Threshold Scores Big With Pancreatic Cancer Data
Ohad Hammer • Mon, Mar 5, 2012 • 9 Comments
Dendreon's Woes Mask The Exciting Opportunities In Immunotherapy Companies
Brian Nichols • Thu, Mar 1, 2012 • 57 Comments
4 Outperforming Biotech Stocks with Bullish Short Trends
Kapitall • Wed, Feb 29, 2012 • 4 Comments
7 Low Risk, Low Debt Stocks With Short Covering
Kapitall • Thu, Feb 23, 2012
Buy Biotech In Phase II For The Best Upside
Brian Nichols • Wed, Feb 22, 2012 • 6 Comments
February's Merger Arbitrage Option Plays
Value Research • Tue, Feb 7, 2012 • 2 Comments
Diversifying Your Portfolio With Biotechnology Stocks
Brian Nichols • Mon, Feb 6, 2012 • 14 Comments
3 M&A Arbitrage Opportunities
The Financial Lexicon • Sun, Feb 5, 2012 • 2 Comments
VIX - Options Volatility Sonar: Tuesday Recap And Amazon Earnings Special
Erick McKitterick • Tue, Jan 31, 2012 • 2 Comments
Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach
Chemistfrog • Mon, Jan 30, 2012 • 1 Comment
Big Biotech Fuels M&A Activity
The Burrill Report • Sun, Jan 29, 2012 • 1 Comment
5 Biotech Stocks With Consistently Rising Liquidity
Kapitall • Wed, Jan 25, 2012 • 1 Comment
6 Biotech Stocks On Impressive Winning Streaks
Kapitall • Mon, Jan 23, 2012
Micromet Signs CRADA with National Cancer Institute to Expand Development of Blinatumomab

Business Wire (Jan 9, 2012)
6 Biotech Stocks With Consistently Rising Liquidity
Kapitall • Thu, Dec 22, 2011 • 1 Comment
5 Winners Of American Society Of Hematology 2011
Ohad Hammer • Mon, Dec 19, 2011 • 6 Comments
Top Fund Buys And Sells In Small Cap Biotechs
GuruFundPicks • Tue, Dec 13, 2011 • 2 Comments
Micromet’s Blinatumomab Produces High Rate of Durable Hematologic Complete Remissions in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Business Wire (Dec 12, 2011)

To learn more about Seeking Alpha Pro, click here.

Micromet Unveils Another Fast Route To Market, Marks Pfizer As Lead Competitor
Ohad Hammer • Sun, Oct 16, 2011 • 14 Comments
Micromet Balances Risk And Reward
Zacks Investment Research • Mon, Sep 12, 2011
The Sky's the Limit for Micromet's BiTE Technology
Prohost Biotech • Thu, Jul 14, 2011 • 6 Comments
Micromet Leads in Bispecific Antibodies
Jason Chew • Wed, May 11, 2011 • 5 Comments
Micromet's BiTE Pipeline Impresses
Zacks Investment Research • Thu, Dec 31, 2009
Micromet: Opportunity Lies in Breakthrough BiTE Antibody
Prohost Biotech • Wed, Dec 16, 2009
Micromet: Drug Development Update
Zacks Investment Research • Tue, Apr 28, 2009
Micromet: Another Seal of Approval
Ohad Hammer • Thu, Aug 21, 2008 • 6 Comments
Micromet Exceeds Expectations, Again
Ohad Hammer • Fri, Jun 6, 2008
Micromet: Biting Cancer (Part II)
Ohad Hammer • Sun, Feb 10, 2008
Micromet, Inc.: The Real Star of ASH 2007
Ohad Hammer • Fri, Dec 14, 2007

Breaking The Mold Of Oncology Drug Development
Brian Nichols • Tue, Apr 10, 2012 • 7 Comments
Upgrades Lead To Optimism In Cancer Stem Cell Therapy
Brian Nichols • Tue, Mar 13, 2012 • 9 Comments
Threshold Scores Big With Pancreatic Cancer Data
Ohad Hammer • Mon, Mar 5, 2012 • 9 Comments
Dendreon's Woes Mask The Exciting Opportunities In Immunotherapy Companies
Brian Nichols • Thu, Mar 1, 2012 • 57 Comments
4 Outperforming Biotech Stocks with Bullish Short Trends
Kapitall • Wed, Feb 29, 2012 • 4 Comments
7 Low Risk, Low Debt Stocks With Short Covering
Kapitall • Thu, Feb 23, 2012
Buy Biotech In Phase II For The Best Upside
Brian Nichols • Wed, Feb 22, 2012 • 6 Comments
February's Merger Arbitrage Option Plays
Value Research • Tue, Feb 7, 2012 • 2 Comments
Diversifying Your Portfolio With Biotechnology Stocks
Brian Nichols • Mon, Feb 6, 2012 • 14 Comments
3 M&A Arbitrage Opportunities
The Financial Lexicon • Sun, Feb 5, 2012 • 2 Comments
VIX - Options Volatility Sonar: Tuesday Recap And Amazon Earnings Special
Erick McKitterick • Tue, Jan 31, 2012 • 2 Comments
Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach
Chemistfrog • Mon, Jan 30, 2012 • 1 Comment
Big Biotech Fuels M&A Activity
The Burrill Report • Sun, Jan 29, 2012 • 1 Comment
5 Biotech Stocks With Consistently Rising Liquidity
Kapitall • Wed, Jan 25, 2012 • 1 Comment
6 Biotech Stocks On Impressive Winning Streaks
Kapitall • Mon, Jan 23, 2012
6 Biotech Stocks With Consistently Rising Liquidity
Kapitall • Thu, Dec 22, 2011 • 1 Comment
5 Winners Of American Society Of Hematology 2011
Ohad Hammer • Mon, Dec 19, 2011 • 6 Comments
Top Fund Buys And Sells In Small Cap Biotechs
GuruFundPicks • Tue, Dec 13, 2011 • 2 Comments
Biotech-Focused Baker Bros.' Top Q3 Picks
GuruFundPicks • Tue, Dec 6, 2011 • 1 Comment
Biotech Trading Vs. Investing 101
Market Shadows • Thu, Oct 13, 2011 • 4 Comments

Micromet, Inc. Q1 2010 Earnings Call Transcript
Wed, May 5, 2010

Increased Merger Activity Expected This Year

at CNBC.com (Feb 24, 2012)
Stocks End Lower as Fed Optimism Fizzles

at CNBC.com (Jan 26, 2012)
Futures Hold Gains After Economic Reports

at CNBC.com (Jan 26, 2012)
Micromet Signs CRADA with National Cancer Institute to Expand Development of Blinatumomab

Business Wire (Jan 9, 2012)
Micromet’s Blinatumomab Produces High Rate of Durable Hematologic Complete Remissions in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Business Wire (Dec 12, 2011)
Micromet’s Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma Patients

Business Wire (Dec 11, 2011)
Micromet Appoints Joseph Lobacki Senior Vice President and Chief Commercial Officer

Business Wire (Dec 5, 2011)
Biotech Stocks: Sanofi, Bayer lead drug-stocks slide

at MarketWatch.com (Jul 11, 2011)
Biotech Stocks: Drug stocks follow broader market south

at MarketWatch.com (Jun 10, 2011)
Movers & Shakers: Wednesday’s biggest advancers and decliners

at MarketWatch.com (Apr 6, 2011)
Mad Mail: Ebix, Micromet, SIGA Technologies and More

at CNBC.com (Apr 1, 2011)
Lightning Round OT: Atlantic Power, Newmont Mining and More

at CNBC.com (Mar 29, 2011)

MITI vs. ETF Alternatives

Company Description

Currently, there's no company description for MITI.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, January 26, 2012, 8:35 AM Micromet (MITI) surges 34% to $11.07, which is just above Amgen's (AMGN) $11/share offer for the company. 1 Comment [Healthcare, Top Stories, M&A]
Thursday, January 26, 2012, 8:20 AM More on Amgen (AMGN) / Micromet (MITI) deal: The acquisition provides Amgen with blinatumomab, a leukemia treatment in Phase 2 trials. The offer of $11/share is a 33% premium to Micromet's close yesterday. (PR) Comment! [Healthcare, Top Stories, M&A]
Thursday, January 26, 2012, 8:08 AM Amgen (AMGN) agrees to acquire Micromet (MITI) for $11/share, or $1.16B. (PR) Comment! [Healthcare, Top Stories, M&A]
Monday, July 11, 2011, 9:13 AM Micromet (MITI) says it entered into a collaboration agreement with Amgen (AMGN) for the research of BiTE antibodies designed to direct the body's cell-destroying T-cells against tumor cells, representing a new therapeutic approach to cancer therapy. MITI +4.5%, AMGN -0.8% premarket. (PR) Comment! [Healthcare, On the Move]
Monday, July 11, 2011, 9:05 AM Premarket gainers: ARJ +11%. AIS +8%. PSTI +6%. MITI +4%. SIRI +3%.
Losers: ING -7%. NBG -6%. BBVA -6%. STD -5%. IRE -5%. TEF -5%. TEF -5%. RENN -5%. E -5%. BCS -4%. DB -4%. LYG -4%. TS -4%. ALU -4%. CTIC -4%. NOK -4%. BUD -4%. TOT -4%. TSEM -4%. SI -3%. FRO -3%. CPST -3%. MT -3%. SDRL -3%. RCL -3%. CS -3%. STO -3%. AMD -3%. UN -3%. SINA -3%. Comment! [On the Move]
Friday, June 10, 2011, 8:54 AM Micromet (MITI +11.5%) says 75% of patients in a small phase-2 trial of its leukemia treatment blinatumomab achieved a complete remission, with no remaining cells in blood or bone marrow. MITI says the results are particularly striking given that the majority of enrolled patients had characteristics typically associated with a dismal outlook. (PR) Comment! [On the Move, Healthcare]
Thursday, November 11, 2010, 9:00 AM Premarket gainers: LVLT +9%. GERN +8%. DNDN +6%. IR +4%.
Losers: ANW -43%. CSCO -17%. MITI -11%. SOLF -10%. RINO -9%. IRE -9%. AIB -8%. TSEM -8%. EXK -8%. CLNE -7%. LLNW -7%. JNPR -6%. ALU -6%. ALTR -5%. GKK -5%. BRCM -4%. CTIC -4%. WPI -4%. TTM -4%. GLP -4%. PCBC -4%. AMSC -4%. STD -4%. ASML -4%. Comment!
Thursday, October 29, 2009, 9:00 AM Premarket gainers: AMSC +15%. AIXG +12%. RBS +12%. PQ +11%. LYG +10%. AKAM +10%. MITI +10%. ING +9%. FNM +8%. ABK +8%. CTIC +8%. DB +8%. FITB +7%. FRE +7%. SWSI +7%. BCS +6%. MOT +6%. IRE +6%. ALU +6%. TCK +5%. RCL +5%. RTP +5%. CS +5%. HL +5%. ACGY +5%. MT +5%. GNW +5%. HGSI +5%. FAS +5%. GOLD +5%. LVS +5%. HIG +5%. MGM +4%. CNO +4%. ASML +4%. NCS +4%. LCC +4%. VALE +4%. PG +4%.
Losers: FSLR -15%. BCRX +4%. FLS -4%. Comment!
Monday, June 8, 2009, 9:21 AM Premarket gainers: PKT +102%. ANPI +56%. MITI +30%. DYAX +18%. SLM +14%. SVA +13%. ARNA +12%. XOMA +9%.
Losers: AIB -13%. LYG -11%. SAY -7%. MT -6%. Comment!

Asif Suria
Amgen to acquire Micromet in an all cash deal for $1.16 billion $AMGN $MITI http://bit.ly/yBPWLQ
1/26/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Asif Suria
Amgen to acquire Micromet in an all cash deal for $1.16 billion $AMGN $MITI http://bit.ly/yBPWLQ
1/26/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jacob Wolinsky
Market New: Jefferies Buying $RBS http://bit.ly/xT9jOd $C $XHB $CP $JEF $BAC $NFLX $FIG $AMGN $MITI
1/26/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

tenax
SEAC and MITI were good to me this morning. rest of the day is gravy
6/10/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dr. Kris
Short Notice: Stocks nearing critical $5 mark: MITI ($5.09), MLNK ($5.47), NVTL ($5.34). All have options but some are thin.
3/15/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Clark
Buy XOM March calls; UNH March calls; TSLA March puts; DSX March puts; MITI March puts; http://seekingalpha.com/p/329a
3/1/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Clark
BUY MITI FEB CALLS. http://seekingalpha.com/p/2rq5
1/17/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Clark
Buy MITI FEB 7.5 CALLS http://seekingalpha.com/p/2quy
1/13/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
ARRY, SNTS, VNDA, DCTH, EXAS, IMMU, MITI, MNKD, ONXX, PCYC, SNTA, ZIOP + others sold off at close, but quickly recovered lost ground. Hmmm.
12/20/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
POST-PULLBACK: ANIK, CYTK, INFI, MITI, SPPI & VNDA - All positioned to move higher through year-end; keep eye on OXGN. => Rx Investors.com
10/19/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

MITI Micromet, Inc.

MITI

Micromet, Inc.